Memolan

Memantine Hydrochloride, the active ingredient in Memolan, is a NMDA receptor antagonist presented as a tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Memolan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memolan is used in the management of Alzheimer’s disease, acting on glutamatergic neurotransmission to improve symptoms.

- Moderate to severe Alzheimer’s disease: helps maintain cognition, daily function and behavior in affected patients. - Alzheimer’s disease with behavioral disturbances: may reduce agitation and improve overall patient stability. - Cognitive decline due to Alzheimer’s disease: supports modest improvements in memory and executive function.

Common Side Effects: - Dizziness: mild to moderate vertigo or light‑headedness. - Headache: transient cranial discomfort. - Constipation: reduced bowel movements. - Confusion: occasional disorientation. - Fatigue: general tiredness. - Hypertension: mild increase in blood pressure.

Serious or Rare Side Effects: - Seizures: rare occurrence of convulsive episodes. - Cardiac arrhythmia: irregular heart rhythms. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes. - Suicidal thoughts: emergent mood changes. - Allergic anaphylaxis: acute hypersensitivity response.

Memolan should be used with consideration of patient‑specific factors and proper storage. - Renal impairment: assess kidney function and adjust therapy as needed. - History of seizures: monitor closely for neurologic events. - Cardiovascular disease: observe blood pressure and heart rhythm. - Concurrent NMDA antagonists: avoid combined use to prevent additive toxicity. - Pregnancy and lactation: safety not established; weigh risks and benefits. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Memolan may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Amantadine: increased risk of central nervous system adverse effects. - Ketamine: additive NMDA antagonism may lead to excessive inhibition. - Other NMDA antagonists: concurrent use can amplify neuro‑psychiatric toxicity.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish therapeutic benefit. - Diuretics: can raise plasma concentrations of memantine. - CNS depressants (e.g., benzodiazepines): monitor for enhanced sedation.